Ameri, A. (1999) The effects of cannabinoids on the brain. Progress in Neurobiology, 58, 315–348.
Ascher, J. A., Cole, J. O., Colin, J. N., et al (1995) Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395–401.
Ashton, C. H. (2001) Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry, 178, 101–106.
Bisaga, A., Comer, S. D., Ward, A. S., et al (2001) The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology (Berl), 157, 1–10.
Boot, B. P., McGregor, I. S. & Hall, W. (2000) MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet, 355, 1818–1821.
Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., et al (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nature Neuroscience, 4, 873–874.
Dahchour, A. & De Witte, P. (2000) Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Progress in Neurobiology, 60, 343–362.
Herz, A. (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology, 129, 99–111.
Jorenby, D. E., Leischow, S. J., Nides, M. A., et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340, 685–691.
Kieffer, B. L. (1999) Opioids: first lessons from knockout mice. Trends in Pharmacological Sciences, 20, 19–26.
Koob, G. F. & Le Moal, M. (2001) Drug addiction, dysregulation of reward, and allostastis. Neuropsychopharmacology, 24, 97–129.
Ledent, C., Valverde, O., Cossu, G., et al (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CBI receptor knockout mice. Science, 283, 401–404.
Louk, J. M. J., Vanderschuren, L. J. & Kalivas, P. W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl), 151, 99–120.
Maldonado, R., Saiardi, A., Valverde, O., et al (1997) Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature, 388, 586–589.
Manzanares, J., Corchero, J., Romero, J., et al (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences, 20, 287–294.
Martin, M., Ledent, C., Parmentier, M., et al (2000) Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CBI knockout mice. European Journal of Neuroscience, 12, 4038–4046.
Nicholson, K. L. & Balster, R. L. (2001) GHB: a new and novel drug of abuse. Drug and Alcohol Dependence, 63, 1–22.
Nutt, D. (1993) Neurochemistry of drugs other than alcohol. Current Opinion in Psychiatry, 6, 395–402.
Nutt, D. (1999) Alcohol and the brain. Pharmacological insights for psychiatrists. British Journal of Psychiatry, 175, 114–119.
Nutt, D. & Malizia, A. L. (2001) New insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder. British Journal of Psychiatry, 179, 390–396.
Pilla, M., Perachon, S., Sautel, F., et al (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature, 400, 371–375.
Reneman, L., Lavalaye, J., Schmand, B., et al (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”): preliminary findings. Archives of General Psychiatry, 58, 901–906.
Rinaldi-Carmona, M., Barth, F., Heaulme, M., et al (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sciences, 56, 1941–1947.
Risinger, F. O., Freeman, P. A., Rubinstein, M., et al (2000) Lack of operant ethanol self-administration in dopamine D2 receptor knockout mice. Psychopharmacology (Berl), 152, 343–350.
Schultz, W. (2001) Reward signaling by dopamine neurons. Neuroscientist, 7, 293–302.
Semple, D. M., Ebmeier, K. P., Glabus, M. F., et al (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users. British Journal of Psychiatry, 175, 63–69.
Strang, J., Bearn, J. & Gossop, M. (1999) Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. American Journal on Addictions, 8, 337–348.
Volkow, N. D., Fowler, J. S. & Wang, G. J. (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. Journal of Psychopharmacology, 13, 337–345.
Wolf, M. E. (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Progress in Neurobiology, 54, 679–720.
Zubieta, J., Greenwald, M. K., Lombardi, U., et al (2000) Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology, 23, 326–334.